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ABSTRACT
Current therapies are inadequate for patients
with severe asthma. The development of
biomarkers and novel targeted therapies
should allow for the introduction of precision
medicine for patients with severe asthma and
the T2 high endotype. However, there remains a
pressing need to better understand the
underlying pathophysiology of T2 low asthma
to help develop better biomarkers and better
treatments for this group of patients. The
emergence of biomarkers may serve value in
characterizing airway disease and in devising
precision approaches to address specific disease
mechanisms. To date, biomarkers remain
somewhat exploratory until further research
can characterize the validity and reliability of
these approaches in improving asthma care.
Partnerships among providers, payers, and
industry will enhance our ability to discover
new approaches that target specific mechanisms
and improve disease outcomes. Ultimately, our
goals are to align phenotypes with endotypes to
direct therapies that will provide the right
intervention at the right time for the right
person with the right diagnosis.
Keywords: Asthma; Asthma-COPD overlap;
Biomarkers; COPD; Severe asthma
INTRODUCTION
Most patients with asthma can be controlled
with currently available therapies. However, an
estimated 3–5%, remain either poorly
controlled or require high doses of
corticosteroids [1]. These patients manifest a
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significant morbidity and decreased quality of
life from the disease and as a consequence of
oral corticosteroids [1]. Patients with severe
asthma may also be at a higher risk of death
[2]. This article is based on previously
conducted studies and does not involve any
new studies of human or animal subjects
performed by any of the authors.
Definition of Severe Asthma
Asthma describes a syndrome for which there
are many causes. This is certainly true of severe
asthma that is not simply a ‘worst form’ of
asthma. Severe asthma can present in different
ways; the 2013 European Respiratory Society/
American Thoracic Society definition of severe
asthma recognizes this and encompasses both
medication burden and level of asthma control
[3]. Severe asthma is defined as asthma that
requires treatment with guideline-suggested
medications for Global Initiative for Asthma
(GINA) steps 4–5 asthma for the previous year or
systemic corticosteroids for at least 50% of the
previous year to prevent it from becoming
uncontrolled or which remains uncontrolled
despite this therapy. Severe asthma is defined as
at least one of the following points:
• Poor symptom control
– Asthma Control Questionnaire (ACQ)
consistently[1.5
– Asthma control test (ACT)\20
– ‘‘Not well-controlled asthma’’ by NAEP/
GINA guidelines
• Frequent severe exacerbations
– C2 bursts of systemic corticosteroids
([3 days each) in the previous year
• Serious exacerbations
– C1 hospitalization, ICU stay or
mechanical ventilation in the previous
year
• Airflow limitation
– After appropriate bronchodilatation
withhold, FEV1\80% of predicted value
(with reduced FEV1/FVC ratio).
The term ‘difficult asthma’ encompasses
patients who do not respond to prescribed
maximum conventional asthma treatment.
This may be due to misdiagnosis (i.e., asthma
is not the primary cause of their symptoms) or
the presence of comorbidities, which are
accountable for a significant proportion of the
symptoms. Alternatively, patients may have
inadequate adherence to therapy. Only after a
full systematic assessment can the diagnosis of
severe asthma be confirmed [4]. The use of the
term ‘brittle asthma’ is unhelpful and should no
longer be used.
Current Treatment Options
For many years there have been limited
therapeutic options for patients with severe
asthma, which has led to an over-reliance on
systemic corticosteroids. The cornerstone of
management should be ensuring that every
patient is on the optimal inhaled
corticosteroid/long-acting beta-agonist com-
bination inhaler for them taking into account
patient preference for delivery device and
dosing frequency. More recently, the addition
of the long-acting muscarinic antagonist,
tiotropium, has been shown to improve
trough FEV1 and increase the time to first
exacerbation by 56 days in patients with severe
asthma [5]. Tiotropium, however, did not
produce a clinically significant improvement
in either ACQ-7 or AQLQ and did not decrease
rescue medication use. At present, tiotropium
remains an add-on therapy with incremental
benefit and is currently the most logical option
at step 4.
Omalizumab, anti-IgE, was the first
monoclonal antibody to be licensed for severe
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asthma. IgE is a logical target given that the
majority of asthmatics are atopic and the
selective blockade of IgE appears to have a
minimal effect on the immune system [6]. We
now have over a decade of experience with
omalizumab and real-world studies have
demonstrated that in carefully selected patient
populations, it is able to decrease exacerbations
and decrease reliance on systemic
corticosteroids [7]. Despite omalizumab’s
obvious benefits, there are several limitations
to its use. The drug is dosed according to body
weight and total serum IgE and is only licensed
for patients allergic to a perennial aeroallergen.
In practice, this means that only roughly 20% of
patients with severe asthma are eligible to trial
the drug. Finally, there is currently no
biomarker to assess response or to determine
length of treatment.
Airways hyperreactivity, a cardinal feature of
asthma, is thought to be due to hyperplasia and
hypertrophy of the airways smooth muscle. This
component of asthma has historically been
treated with both short- and long-acting
bronchodilators. The rationale for bronchial
thermoplasty is predicated on its ability to
selectively decrease airways smooth muscle
without affecting airway epithelium. The
well-designed AIR2 study was negative for its
primary endpoint of AQLQ, but does significantly
decrease healthcare utilization [8]. The primary
concern with bronchial thermoplasty is that, at
present, it isnotpossible topredictwhichpatients
will respond to this invasive procedure that
requires three bronchoscopies.
From Phenotypes to Endotypes
to Precision Medicine with Logical
Targeted Therapies
Asthma is a syndrome that comprises the
symptoms of asthma and variable airflow
obstruction, for which there are several
different causes. In an attempt to characterize
the different causes of the syndrome, asthma
was initially categorized into phenotypes
depending on observable characteristics with
no direct relationship to the underlying disease
process, e.g., early versus late-onset or atopic
versus non-atopic. More recently, asthma
endotypes have been described, which
acknowledges that distinct disease entities may
be present in clusters of phenotypes, but each is
defined by a specific biological mechanism, e.g.,
severe late-onset hyper-eosinophilic asthma [9].
The actual benefit of endotypes to the patient
and clinician lies in accurately identifying the
underlying biology, which allows for the
generation of biomarkers and targeted therapy
for an individual patient, what has more
recently been described as precision medicine.
The only useful endotype at present is the T2
high endotype, which is associated with
increased levels of Th2 cytokines such as
interleukin (IL)-4, IL-5, and IL-13 [10]. The T2
high endotype has been derived from the
seminal finding that the expression of
IL-13-induced genes in airway epithelial cells
can be divided by hierarchical clustering into
individuals that express high levels of periostin,
CLCA1, and SerpinB2 (Th2 high) and those
with low levels of expression (Th2 low) [11].
Markers of allergy, eosinophilic inflammation,
and airways remodeling are increased in Th2
high asthma and only Th2 high asthmatics
demonstrated an improvement in FEV1 in
response to a trial of inhaled corticosteroids
[11]. This endotype has been further refined
from Th2 high to type 2 high by the discovery
of innate lymphoid cells type 2 (ILC2), which
although are present in relatively low numbers
produce a large amount of Th2 cytokines [12].
Multiple targeted therapies against the T2
high endotype are being produced, the first of
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which are now licensed for use in severe
asthma. Multiple selective anti-eosinophilic
therapies have been produced. The eosinophil
appears to play a major role as an effector cell in
T2 high asthma and is a logical target for novel
severe asthma therapies. Two humanized
monoclonals against IL-5 have been produced,
mepolizumab and reslizumab, and following
successful phase III programs are licensed for
use in severe eosinophilic asthma.
Mepolizumab decreases asthma exacerbations
when compared with placebo [13] and has
demonstrated efficacy in oral corticosteroid
sparing following four weekly subcutaneous
injections [14]. The magnitude of the benefit
frommepolizumab appears to correlate with the
blood eosinophil level [15]. Reslizumab has
demonstrated a significant improvement in
FEV1 and decrease in asthma exacerbations
following 4 weekly intravenous infusions [16].
Benralizumab has a different mechanism
of action in that it binds to the IL-5Ra and
depletes eosinophils via antibody-dependent
cell-mediated cytotoxicity. Published evidence
suggests that this mechanism of action may be
more effective than IL-5 blockade, as
benralizumab produced a 95.8% reduction in
airway eosinophils [17] compared with 55%
seen with mepolizumab [18]. Two replicate
studies of benralizumab have demonstrated a
significant decrease in asthma exacerbations
with a concomitant improvement in FEV1
produced by 8 weekly subcutaneous dosing
[19, 20].
IL-13 has multiple effects on the asthmatic
airway including increased mucus production,
airways hyperresponsiveness, and airway
inflammation [21], making it a logical target
to pursue in clinical trials. The results of IL-13
blockade have been mixed with the two phase
III pivotal trials for lebrikizumab, producing
underwhelming results [22], compared with
positive results from the phase IIb studies of
Dupilumab (combined IL-4 and IL-13 blockade)
[23] and tralokinumab, which has the potential
benefit of a companion biomarker, Dipeptidyl
peptidase-4 [24].
BIOMARKERS PREDICTING
RESPONSES IN SEVERE ASTHMA
The management of chronic disease requires
metrics to assess therapeutic responses and
prognosis. The heterogeneity of disease
pathogenesis and response to treatment poses
challenges when considering ‘‘one treatment
fits all’’ approaches [25]. Optimally, the health
provider seeks predictive attributes of a patient
that enhance the likelihood of treatment
success while decreasing adverse effects.
Unfortunately, current disease management
algorithms embrace a trial-and-error mandate
that decreases patient adherence and increases
adverse effects and health care costs.
What are Biomarkers?
Generally, health care professions group
patients according to clinical characteristics,
termed phenotypes. Contemporary thought
however strives to stratify clinical responses to
treatment by underlying mechanisms, i.e.,
endotypes, to define heterogeneity of disease.
Such mechanisms may also define biomarkers
that describe genetic, pharmacologic, biologic,
or immunologic attributes. In this manner,
clarity, fidelity, and prediction of treatment
response can be attained [26, 27].
Regulatory agencies have established criteria
to assess approval of biomarkers defined as
characteristics that objectively measure and
evaluate an indicator of a normal biological
process, or pharmacologic response to a
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therapeutic intervention [27, 28]. The
characteristics of an ideal biomarker should
confirm a diagnosis, change with disease
activity, identify clinical or treatment
responses, be non-invasive, inexpensive, and
easy to collect and measure [29].
The value of biomarkers has shifted the focus
of asthma research from a broad perspective
that studies symptom expression, lung
function, and medication response to the use
of cellular profiles, protein analyses, and genetic
markers alone or in combination [29].
Currently, there exist emerging biomarker
approaches using sputum (cell counts),
exhaled air (FeNO, pH, proteins), saliva
(genotypes), urine (leukotrienes), and
peripheral blood (cell counts, periostin, IgE,
ECP) [30]. Arguably, a single biomarker will be
inadequate to completely profile a specific
endotype and thus a multidimensional
approach will enhance the predictive strength
for diagnosis and treatment of asthma. Further,
the development of biological therapies in
severe asthma, which are substantially more
costly than small molecule approaches, has
necessitated the development of new metrics
that predict therapeutic responses to these
agents.
Current Use
The identification, development, and
utilization of biomarkers may overcome
barriers that hinder the clinical management
of severe asthma. The National Institutes of
Health in conjunction with other federal
agencies convened an expert panel to evaluate
the utility of biomarkers and to standardize
asthma outcomes in clinical research studies
[31]. The goal of this committee was to critically
evaluate biomarkers relevant to the underlying
disease process, progression, and response to
therapy for severe persistent asthma.
Biomarkers were characterized according to
three categories that included: Core, required
for clinical trials based on large observational
trials; Supplemental, demonstrated validity but
optional for trials; or Emerging, potential to
expand or improve disease monitoring but not
yet standardized and require further
development. The following discussion will
review the validity and reliability of selected
biomarkers in severe persistent asthma.
Multiallergen Screen (IgE)
Evidence suggests that asthma pathogenesis can
be broadly characterized as atopic or non-atopic
and that these categories predict therapeutic
responses and prognosis [27, 28]. Subjects with
Th2-driven disease often manifest high
allergen-specific IgE and elevated levels of IL-4,
IL-5, and IL-13 [27]. An expert panel suggested
that multiallergen screen (IgE) can serve as a
core biomarker for atopic asthma [31]. The IgE
level defines the individual as atopic but does
not specify the allergen(s) to which the patient
is sensitive [31]. Since geographic and
demographic diversity is allergen-specific, IgE
and/or skin testing for allergens were
considered supplemental biomarkers [31].
Fractional Exhaled Nitric Oxide (FeNO)
The levels of nitric oxide (NO) in the airways
and in exhaled gas correlates with airway
inflammation and NO levels are diminished by
anti-inflammatory medications [27, 28].
Although most cells can generate NO, the
airway epithelium contributes predominately
to exhaled NO levels as measured by current
approaches [27]. Collectively, quantitative
measurement of airway NO is considered an
indirect marker of airway inflammation [31].
Although considered a valuable tool in assessing
asthma control and atopy especially in pediatric
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patients, there exists inconsistency in
characterizing severe asthma and in asthma
patients who smoke [31]. Evidence also suggests
that FeNO levels are high in atopic subjects
without asthma. The measurements require
sophisticated instrumentation, and the
correlation of FeNO levels with specific asthma
phenotypes and airway remodeling remain
unclear [32]. Collectively, these limitations
suggest that FeNO should be a supplemental
biomarker in severe asthma [31].
Eosinophils
Eosinophils, bone marrow-derived
granulocytes, modulate the function of
structural cells and immunocytes and play
critical roles in host defense against virus and
bacteria, in the homeostasis of innate and
adaptive immunity, and in tissue and vascular
remodeling. Dysregulated eosinophilia,
however, evokes pathology such as asthma,
nasal polyps, vasculitis, and atopic dermatitis
[33, 34]. Using bronchial biopsies, investigators
showed that numbers of inflammatory cells
including eosinophils were elevated in subjects
with atopic asthma when compared with those
who were non-atopic or healthy [35]. Others
determined that severe persistent asthma
subjects could be divided into those with or
without airway tissue eosinophils [36].
Importantly, therapeutic strategies that
decreased sputum eosinophil levels, a
surrogate of airway eosinophilia, markedly
improved pulmonary function and
exacerbation rates in comparison to subjects
who were treated by guidelines alone.
Unfortunately, accessibility to testing sputum
or tissue eosinophil levels remains reserved for
research purposes and requires substantial
expertise. Accordingly, investigators have
extensively studied the validity and reliability
of blood eosinophil levels as a biomarker of
disease onset and severity [31]. Using
monoclonal antibodies, recent studies show
that targeting IL-5, an important survival
factor for eosinophils, decreased blood
eosinophil counts that were associated with
markedly improved exacerbation rates, patient
reported outcomes and pulmonary function as
compared with subjects treated with standard
care [27, 32]. Unfortunately, limitations exist in
using blood eosinophil counts as severe asthma
biomarkers that include: diurnal variations in
blood eosinophil levels, sensitivity to systemic
glucocorticoids, and lack of concordance
between sputum and blood levels [31, 37].
These limitations suggested that blood
eosinophil counts should serve as
supplemental biomarkers [31].
Emerging Biomarkers
The development of novel therapies including
biologic agents provide clinical platforms for
discovery of biomarkers that predict therapeutic
responses [25]. Essentially, biologics can serve as
human knockouts of target proteins or cells. In
severe persistent asthma, the recognition that
monoclonal antibodies targeting IL-5 and IL-13
signaling pathways improved disease outcomes
identified eosinophils, periostin, or dipeptidyl
peptidase-4 (DPP4) as potential biomarkers,
respectively [27]. Serum levels of periostin, an
extracellular matrix protein induced by
interleukin IL-4 and IL-13 in airway epithelial
cells and lung fibroblasts, correlated with
Th2-driven airway inflammation and with
airway eosinophil numbers [27, 38]. Evidence
also suggests serum periostin may predict the
response to targeted therapy with biologic
agents such as tralokinzamab (anti-IL-13) and
omalizumab (anti-IgE) [27, 38]. The protein
encoded by the DPP4 gene, which is induced
by IL-13, represents an antigenic enzyme
expressed on the surface of most cell types and
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modulates immune regulation, signal
transduction, and apoptosis. Serum levels of
DPP4 correlated with Th2-associated
inflammation and serum periostin [38].
Although periostin and DPP4 serve as
predictors of Th2-associated airway
inflammatory responses, neither are approved
biomarkers and both are affected by myriad
processes unassociated with asthma [27]. Other
emerging biomarkers include imaging
techniques such as high-resolution CT
scanning or optical coherence tomography
(OCT) that can measure lung density (air
trapping), airway lumen size, and wall
thickness—metrics of airway remodeling.
Unfortunately, OCT requires bronchoscopy,
and CT scanning necessitates more validation
and reproducibility before the risk of exposure
to ionizing radiation justifies the repetitive
measures of characterizing asthma outcomes
[31].
ASTHMA OR COPD?
Throughout the years, attempts have focused
on finding specific disease characteristics in
order to establish whether a specific patient
has asthma or COPD. The definitions of asthma
and COPD have similarities which make
differential diagnosis difficult. Both asthma
and COPD are heterogeneous, chronic, and
inflammatory diseases. The same type of
inflammatory cells may be active in asthma
and COPD and inflammatory features do not
always clearly differ between the two diseases.
Both diseases are characterized by airflow
obstruction, which may be variable and
persistent, i.e., not fully reversible. Although
the variability of symptoms over time usually is
more common in asthma, many COPD patients
also experience variability of symptoms.
Chronic obstructive pulmonary disease is often
caused by harmful exposure, predominantly
smoking, whereas in asthma the cause is not
clear and the development of irreversible airway
obstruction seems to be related to eosinophilic
inflammation [39]. Many subjects with asthma
are smokers, which may complicate disease
characteristics. It has been reported that
around 20% of the asthmatic subjects are
smokers [40], which may negatively influence
clinical outcomes such as quality of life and
need for hospital care due to asthma [41].
During recent years, the overlap between
asthma and COPD has attracted increasing
interest and has, in some contexts, been called
asthma-COPD overlap syndrome (ACOS).
Recently, international guidelines for
management of conditions with this overlap
have been published [42, 43]. A substantial
number of patients classified as having asthma
also have features of COPD and many patients
classified as having COPD also have features of
asthma, and patients with asthma seem to run
an increased risk of developing emphysema
[44]. As these patients do not fulfill the
separate criteria for either asthma or COPD,
they have been excluded from randomized
clinical asthma and COPD trials. Thus, the
knowledge of how to treat patients with
features of both asthma and COPD is limited.
Clinical Aspects on Asthma—COPD
Overlap
A recent overview reported that the incidence of
the asthma/COPD overlap phenotype is
approximately 20% in patients with the
diagnosis of asthma or COPD [45]. In severe
asthma the overlap phenotypewas characterized
by severe airflow obstruction and almost half of
the patients were on maintenance treatment
with oral steroids [45]. In studies of adult asthma,
the overlap phenotypes had more severe airflow
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obstruction and were equally male and female,
whereas there was a male predominance for
overlap in COPD [45]. COPD patients who also
have features of asthma haveworse quality of life
and experience more severe exacerbations,
leading to more hospitalizations than patients
with ‘‘pure’’ COPD [45–47]. The occurrence of
emphysema does not seem to differ much
between patients with COPD and patients with
asthma-COPD overlap, indicating that airflow
limitation in these patients to a large extent is
associated with small airways disease [46].
Lung Function
Bronchodilation, assessed as improvement of
FEV1 following inhalation of bronchodilators,
has been claimed to be a useful tool for
differentiating between asthma and COPD.
Bronchodilator reversibility is, however, not a
constant feature, as it varies over time [48] and
is therefore not a reliable diagnostic measure.
Furthermore, FEV1 increases more than 12%
and 200 ml after bronchodilatation in more
than half of the COPD patients [49].
Most asthmatic patients have variable airway
obstruction with normal lung function during
remission. There are, however, patients with
asthma who develop irreversible airflow
limitation over time [50, 51]. Asthma patients
who develop fixed airflow limitation seem to
have lower lung function and bronchodilator
response at a younger age and they suffer from
more symptoms such as cough and phlegm
production [51].
In 1977, Fletcher and Peto showed that
smokers with COPD exhibit a faster lung
function (FEV1) decline over time than do
non-smokers [52]. The rapid lung function
decline is, however, not an exclusive feature of
patients with COPD; it has been shown that
non-smoking asthma patients have a more
rapid lung function decline over time than
non-asthmatic subjects [53].
Inflammation in Asthma and COPD
Half of the patients with asthma exhibit a
persistent eosinophilic condition [54], which
implies that half of asthma patients may have a
non-eosinophilic inflammation that may
respond poorly to traditional
anti-inflammatory treatment such as steroids.
Previous studies showed that patients with
COPD may have increased the number of
eosinophils in the airway and peripheral
circulation [55, 56] and eosinophilia may also
appear in association with acute exacerbations
[57].
In COPD, neutrophils may play an
important role in mediating airway
inflammation. Asthma may, however, also be
associated with neutrophil inflammation,
which is primarily associated with severe
asthma [36, 58, 59] but may also be found in
more mild disease [54] and in smokers with
asthma [60].
Systemic inflammation is most often
assessed by measurement of circulating
inflammatory cells, cytokines, and acute phase
proteins. It is associated with poor prognosis
and increased all-cause mortality and seems to
be present in two of three individuals with
COPD, implying that approximately 30% of
subjects with COPD do not have signs of
systemic inflammation. Systemic inflammation
is, however, not a constant feature and only one
out of six COPD patients has signs of persistent
systemic inflammation, which does not seem to
be related to disease severity assessed by lung
function measurement [61]. The variation of
systemic inflammation in COPD is associated
with ongoing infection and is enhanced in the
presence of airway pathogens [62]. In asthma,
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systemic inflammation has not been studied
much. Apart from an increased number of
circulating eosinophils in some patients, there
is no clear systemic inflammatory pattern in
asthma.
Treatment of Patients with Features
of Asthma and COPD
The consequences of the strict inclusion and
exclusion criteria in asthma and COPD trials
have resulted in limited knowledge on how to
treat these patients.
The finding that COPD patients with sputum
and/or blood eosinophilia respond better to
steroids than do COPD patients without
eosinophilia [63, 64] supports that patients
with features of both asthma and COPD likely
will benefit from treatment with inhaled
steroids. It has been demonstrated that the
response to steroid treatment in asthma is
impaired in smokers [60, 65]. To our
knowledge, there is no study in which the
steroid response has been compared in
non-smoking and smoking patients with
COPD or asthma-COPD overlap.
Although specific studies are sparse, it is
reasonable to assume that patients with features
of both asthma and COPD will benefit from
maintenance therapy with inhaled long-acting
bronchodilators. Studies of other
pharmacologic treatment alternatives are
lacking, and there are no data on the effect of
leukotriene antagonists, PDE4-inhibitors, and
biologic drugs in this particular group of
patients.
Asthma/COPD Overlap
To date, there is not one specific entity defined
as asthma-COPD overlap syndrome. Patients
who manifest asthma and COPD characteristics
represent a number of different phenotypes
with various clinical pictures, inflammatory
profiles, physiological features, and prognoses;
asthma-COPD overlap is not a unique
syndrome. Expressions of pathologic
conditions are defined by the genetic profile
and environmental factors. Each individual
has unique combinations of genetic
and environmental factors, which result
in expression of different pathologic
conditions (Fig. 1). In many subjects,
genetic-environmental combinations include a
condition that is recognized as asthma, e.g.,
young, allergic subjects with typical symptoms
which we associate with asthma. A non-allergic,
heavy smoker who develops dyspnea and
airway obstruction at the age of 50 years is
easily recognized as COPD. There are, however,
a number of individuals who develop
pathologic conditions that are not clearly
within our definitions of asthma or COPD.
These patients constitute a heterogeneous
group and represent a number of different
pathologic conditions. Therefore, for two
reasons, the expression asthma-overlap
syndrome should not be used. First, because it
does not constitute one single condition but
several conditions, and second, it is not a
syndrome. Further efforts must be focused on
defining different subgroups of obstructive lung
diseases in order to enable tailoring
individualized treatment for the different
groups of patients.
CONCLUSIONS
Current therapies are inadequate for patients
with severe asthma. The development of
biomarkers and novel targeted therapies
should allow for the introduction of precision
medicine for patients with severe asthma and
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the T2 high endotype. However, there remains a
pressing need to better understand the
underlying pathophysiology of T2 low asthma
to help develop better biomarkers and better
treatments for this group of patients.
The emergence of biomarkers may serve
value in characterizing airway disease and in
devising precision approaches to address
specific disease mechanisms. To date,
biomarkers remain somewhat exploratory until
further research can characterize the validity
and reliability of these approaches in improving
asthma care. Partnerships among providers,
payers, and industry will enhance our ability
to discover new approaches that target specific
mechanisms and improve disease outcomes.
Ultimately, our goals are to align phenotypes
with endotypes to direct therapies that will
provide the right intervention at the right time
for the right person with the right diagnosis.
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